LucentAD® Complete:

A new standard in Alzheimer's testing

Through an exclusive collaboration with Lucent Diagnostics, we’re proud to offer LucentAD® Complete to patients and healthcare providers across the UK. This advanced, multi-marker blood test is specifically designed to aid in Alzheimer’s disease diagnostics, bringing a new level of accuracy and patient accessibility to the field.

Proven Accuracy

With 90% accuracy and a non-invasive testing process, LucentAD® Complete provides a reliable, accessible, and patient-friendly option to assist in early Alzheimer’s detection.

Read White Paper

Extensive Validation

LucentAD® Complete offers an unparalleled solution for assessing the risk of amyloid pathology in patients with mild cognitive impairment (MCI) or early cognitive symptoms. This blood test is backed by clinical validation and is a preferred alternative to more invasive and costly diagnostic methods, such as cerebrospinal fluid (CSF) testing and PET imaging.

View Product Guide

Cost Effective

LucentAD® Complete is an affordable option that makes amyloid pathology risk assessment more accessible to a larger number of patients who are experiencing symptoms.

Non-Invasive

The test requires only a blood sample, significantly reducing patient discomfort and procedural risks associated with gold standard CSF or PET.

High Sensitivity and Specificity

Utilizing a multi-marker approach, LucentAD® Complete achieves accuracy that meets or exceeds the thresholds recommended by leading Alzheimer’s research bodies, including the Global CEO Initiative on Alzheimer’s Disease (CEOi).

Streamlined Testing & Results

The test offers a quick 15 working day turnaround, with results presented as a clear amyloid risk score that is accessible through a secure portal.

Multi-Marker Strategy

LucentAD® Complete is an algorithmic, multi-analyte test designed to accurately classify amyloid status by quantifying multiple biomarkers. This approach combines p-Tau 217 (a highly accurate marker of Alzheimer’s amyloid pathology) with additional plasma biomarkers, including Nfl, Aβ42/40 ratio, and GFAP*. Together, these biomarkers improve the diagnostic clarity, especially in cases that might otherwise yield inconclusive results with p-Tau 217 alone.

pTau-217

This biomarker provides the primary basis for amyloid classification due to its high correlation with amyloid PET imaging. Phosphorylated tau at the 217 position is recognized as a leading plasma biomarker for Alzheimer’s disease detection.

NfL

(Neurofilament Light Chain). Provides additional information on neurodegeneration, enabling further discrimination in cases of cognitive impairment.

Aβ42/40 Ratio

Directly reflecting amyloid plaque pathology, this ratio is used to further enhance accuracy.

GFAP

(Glial Fibrillary Acidic Protein). Reflects astrocytic activation associated with Alzheimer’s pathology.

These biomarkers are processed through the Lucent Diagnostics Simoa® technology for ultra-sensitive detection, achieving levels of precision necessary for clinical use. Through a logistic regression model, the test assigns an amyloid risk score between 0 and 100, categorizing results into low, intermediate, or high risk.

*GFAP is offered pursuant to a license from Banyan Biomarkers Inc. Banyan GFAP is a registered trademark of Banyan Biomarkers.

Clinical Validation & Performance

LucentAD® Complete has undergone validation across multiple independent cohorts, ensuring robust performance across diverse patient populations. Studies indicate:

90% Accuracy: High levels of sensitivity and specificity in amyloid classification, aligning with standards set by the Global Initiative.

Reduced Intermediate Zone: The inclusion of multi-marker analysis reduces the "intermediate" diagnostic range by approximately three-fold, providing more conclusive results for a larger proportion of patients.

Read The White Paper

Patient Criteria & Use Cases

The test serves as an adjunct to clinical assessment, providing valuable insights to guide patient management. In cases where the score falls within the “intermediate” risk range, follow-up with CSF or PET may be recommended to confirm amyloid pathology.

Cognitive Impairment

Ideal for patients with MCI or early cognitive symptoms, for whom early diagnosis may enable timely therapeutic intervention.

High Alzheimer's Risk

Individuals with High Alzheimer’s Risk: Includes patients with a family history or genetic predisposition to Alzheimer’s disease who are displaying symptoms.

Avoid Invasive Procedures

Especially beneficial for patients with contraindications to lumbar puncture or those unable to access PET imaging.